Objective To study the relationship between the suppression of the hypothalamic-pituitary-gonadal axis (HPGA) and the predicted adult height (PAH) in girls with central precocious puberty (CPP) during the treatment with gonadotropin-releasing hormone analogue (GnRHa), in order to provide guidance for individualized GnRHa dose adjustment in clinical practice. Methods The clinical data of 75 CPP girls were collected, and then height, bone age (BA), uterine and ovarian volumes, and peak luteinizing hormone (LH), peak follicle-stimulating hormone (FSH), and estradiol (E2) levels were recorded at different time points of GnRHa treatment. PAH at each time point was calculated. PAH improvement (ΔPAH=PAH-target height) and its relationship with the degree of HPGA suppression were analyzed. Threshold effect analysis was applied to determine the best HPGA suppression range forΔPAH. Results After GnRHa treatment, PAHs were improved markedly compared with the data in the early stage of treatment. ΔPAH showed a negative correlation with ΔBA. At 24 months of treatment, ΔPAH was also negatively correlated with LH. Uterine volume controlled between 2.3 and 3.0 mL, LH level controlled below 0.8 IU/L, and FSH controlled below 2.4 IU/L could slow down the growth of BA and improve PAH. Conclusions GnRHa treatment can improve the PAH of CPP girls. Selection of an appropriate therapeutic dose for GnRHa to control uterine volume, LH and FSH levels within certain ranges can slow down the growth of BA and improve PAH.
Key words
Gonadotropin-releasing hormone analogue /
Central precocious puberty /
Hypothalamic-pituitarygonadal axis /
Predicted adult height /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 陈秋莉, 马华梅, 李燕虹, 等. 促性腺激素释放激素类似物改善中枢性性早熟和快速进展型早发育女孩成年身高:单中心15年102 例病例追踪研究[J]. 中华内分泌代谢杂志, 2013, 29(3):236-240.
[2] Kim EY. Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty[J]. Korean J Pediatr, 2015, 58(1):1-7.
[3] Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children[J]. Pediatrics, 2009, 123(4):e752-e762.
[4] 中华医学会儿科学分会内分泌遗传代谢学组. 中枢性( 真性) 性早熟诊治指南[J]. 中华儿科杂志, 2007, 45(6):426-427.
[5] 杜敏联. 根据G-P 图谱测骨龄法预测成年身高表[M]//杜敏联. 青春期内分泌学. 北京:人民卫生出版社, 2006, 417-418.
[6] Ziereisen F, Guissard G, Damry N, et al. Sonographic imaging of the pediatric female pelvis[J]. Eur Radiol, 2005, 15(7):1296-1309.
[7] 梁雁, 应艳琴, 罗小平. 儿童性早熟诊断和治疗中应该重视的问题[J]. 中华儿科杂志, 2011, 49(6):401-404.
[8] Allali S, Lemaire P, Couto-Silva AC, et al. Predicting the adult height of girls with central precocious puberty[J]. Med Sci Moni, 2011, 17(6):41-48.
[9] 赵兰, 钟燕. 中枢性性早熟对儿童体格及性发育的影响[J]. 中国当代儿科杂志, 2014, 16(5):555-559.
[10] Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin releasing hormone analogs[J]. Clin Endocrinol Metab, 2008, 93(7):2662-2669.
[11] Fuld K, Chi C, Neely EK. A randomized trial of 1-and 3-month depot leuprolide doses in the treatment of central precocious puberty[J]. J Pediatr, 2011, 159(6):982-987.
[12] 张庆, 郑名芳, 高峻, 等. 正常女童生殖器超声多参数的检测[J]. 中华医学超声杂志( 电子版), 2009, 6(6):1057-1064.
[13] Kim YJ, Lee HS, Lee YJ, et al. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty[J]. Ann Pediatr Endocrinol Metab, 2013, 18(4):173-178.
[14] Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty;validity of single luteinizing hormone measurement after leuprolide acetate injection[J]. Clin Endocrinol (Oxf), 2012, 76(1):126-130.
[15] 蔡锡顶, 朱蓓, 李珍, 等. LHRH 激发试验对性早熟女童 GnRHa 治疗的评估[J]. 临床儿科杂志, 2013, 31(12):1121-1124.
[16] Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty:hormonal suppression and recovery[J]. Int J Pediatr Endocrinol, 2010, 2010:398639.
PDF(1403 KB)
